Company intelligence / Profile preview

Cadre Bioscience

St. Louis, Missouri, USAcadrebioscience.com ↗

Ownership: Private
Employees: ~15
Development stage: Other

Overview

Cadre Bioscience accelerates the development of diverse early-stage therapeutic assets by licensing or optioning technologies from leading research institutions. The company has received SBIR funding to develop a novel anti-tumor drug with both direct and immune-modulating effects. No published clinical results yet; programs are at preclinical/early stage

Therapeutic areas: Oncology
Modalities: Small moleculesAntibodiesVaccines
Industry: Biotech

Partnerships

BioGenerator VenturesCollaborations with top-tier universities for technology sourcing

Beyond the preview

Go deeper on Cadre Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cadre Bioscience.

Explore the full profile